Treatment of Helicobacter pylori in surgical practice: A randomised trial of triple versus quadruple therapy in a rural district general hospital

World Journal of Gastroenterology

Volumn 14, Issue 24, 2008, Pages 3855-3860

  Ching, Siok Siong ^a   Sabanathan, Sivakumaran ^b   Jenkinson, Lloyd R ^b  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

^b Department of Surgery ^*  (United Kingdom)

Author keywords

Eradication rate; Helicobacter pylori; Quadruple therapy; Side effects; Treatment compliance; Triple therapy

Indexed keywords

AMOXICILLIN; BISMUTH CITRATE; CLARITHROMYCIN; HELICLEAR; LANSOPRAZOLE; METRONIDAZOLE; TETRACYCLINE; UNCLASSIFIED DRUG;

ADULT; ARTHRALGIA; ARTICLE; BACTERIAL INFECTION; BLACK STOOL; BLURRED VISION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; ERADICATION THERAPY; FECES COLOR; FEMALE; GENERAL HOSPITAL; GLOSSITIS; HAIRY TONGUE; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; MOUTH PAIN; NAUSEA; PATIENT COMPLIANCE; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TASTE DISORDER; UNITED KINGDOM; UREA BREATH TEST; VOMITING; XEROSTOMIA;

EID: 54349094077     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.14.3855     Document Type: Article

References (34)

1. de Boer WA, Driessen WM, Potters VP, Tytgat GN. Randomized study comparing 1 with 2 weeks of quadruple therapy for eradicating Helicobacter pylori. Am J Gastroenterol 1994; 89: 1993-1997
2. Calvet X, Garcia N, Gene E, Campo R, Brullet E, Sanfeliu 1. Modified seven-day, quadruple therapy as a first line Helicobacter pylori treatment. Aliment Pharmacol Ther 2001; 15: 1061-1065
3. de Boer SY, v d Meeberg PC, Siem H, de Boer WA. Comparison of four-day and seven-day pantoprazole-based quadruple therapy as a routine treatment for Helicobacter pylori infection. Neth J Med 2003; 61: 218-222
4. Buring SM, Winner LH, Hatton RC, Doering PL. Discontinuation rates of Helicobacter pylori treatment regimens: a meta-analysis. Pharmacotherapy 1999; 19: 324-332
5. Fennerty MB, Lieberman DA, Vakil N, Magaret N, Faigel DO, Helfand M. Effectiveness of Helicobacter pylori therapies in a clinical practice setting. Arch Intern Med 1999; 159: 1562-1566
6. Laine L, Hunt R, El-Zimaity H, Nguyen B, Osato M, Spenard J. Bismuth-based quadruple th erapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. Am J Gastroenterol 2003; 98: 562-567
7. Fischbach LA, van Zanten S, Dickason J. Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies. Aliment Pharmacol Ther 2004; 20: 1071-1082
8. Laine L, Frantz JE, Baker A, Neil GA. A United States multicentre trial of dual and proton pump inhibitor-based triple therapies for Helicobacter pylori. Aliment Pharmacol Ther 1997; 11: 913-917
9. Comet R, Calvet X, Navarro M, Garcia N, Sanfeliu I. [Seven-day omeprazole, clarithromycin, and amoxicillin for the therapy of Helicobacter pylori infection] Gastroenterol Hepatol 1998; 21: 81-83
10. Pipkin GA, Williamson R, Wood JR. Review article: one-week clarithromycin triple therapy regimens for eradication of Helicobacter pylori. Aliment Pharmacol Ther 1998; 12: 823-837
11. Calvet X, Lopez-Lorente M, Cubells M, Bare M, Golvez E, Molina E. Two-week dual vs. one-week triple therapy for cure of Helicobacter pylori infection in primary care: a multicentre, randomized trial. Aliment Pharmacol Ther 1999; 13: 781-786
12. Elviss NC, Owen RJ, Xerry J, Walker AM, Davies K. Helicobacter pylori antibiotic resistance patterns and genotypes in adult dyspeptic patients from a regional population in North Wales. J Antimicrob Chemother 2004; 54: 435-440
13. Chisholm SA, Teare EL, Davies K, Owen RJ. Surveillance of primary antibiotic resistance of Helicobacter pylori at centres in England and Wales over a six-year period (2000-2005). Euro Surveill 2007; 12: E3-E4
14. Gisbert JP, Gisbert JL, Marcos S, Gravalos RG, Carpio D, Pajares JM. Seven-day 'rescue' therapy after Helicobacter pylori treatment failure: omeprazole, bismuth, tetracycline and metronidazole vs. ranitidine bismuth citrate, tetracycline and metronidazole. Aliment Pharmacol Ther 1999; 13: 1311-1316
15. Lee JM, Breslin NP, Hyde DK, Buckley MJ, O'Morain CA. Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice. Aliment Pharmacol Ther 1999; 13: 489-496
16. Gomollon F, Ducons JA, Ferrero M, Garcia Cabezudo J, Guirao R, Simon MA, Montoro M. Quadruple therapy is effective for eradicating Helicobacter pylori after failure of triple proton-pump inhibitor-based therapy: a detailed, prospective analysis of 21 consecutive cases. Helicobacter 1999; 4: 222-225
17. Sicilia B, Sierra E, Lago A, Villar M, Garcia S, Gomollon F. [High eradication rates in Helicobacter pylori infection in patients with duodenal ulcer who failed previous eradication therapy] Med Clin (Bare) 2000; 115: 641-643
18. Boixeda D, Bermejo F, Martin-De-Argila C, Lopez-Sanroman A, Defarges V, Hernandez-Ranz F, Milicua JM, Garcia-Plaza A. Efficacy of quadruple therapy with pantoprazole, bismuth, tetracycline and metronidazole as rescue treatment for Helicobacter pylori infection. Aliment Pharmacol Ther 2002; 16: 1457-1460
19. Lam SK, Talley NJ. Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol 1998; 13: 1-12
20. Gisbert JP, Calvet X, Gomollon F, Sainz R. [Treatment for the eradication of Helicobacter pylori. Recommendations of the Spanish Consensus Conference] Med Clin (Barc) 2000; 114: 185-195
21. Malfertheiner P, Megraud F, O'Morain C, Hungin AP, Jones R, Axon A, Graham DY, Tytgat G. Current concepts in the management of Helicobacter pylori infection-the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002; 16: 167-180
22. Hunt R, Fallone C, Veldhuyzan van Zanten S, Sherman P, Smaill F, Flook N, Thomson A. Canadian Helicobacter Study Group Consensus Conference: Update on the management of Helicobacter pylori-an evidence-based evaluation of six topics relevant to clinical outcomes in patients evaluated for H pylori infection. Can J Gastroenterol 2004; 18: 547-554
23. Vilaichone RK, Mahachai V, Graham DY. Helicobacter pylori diagnosis and management. Gastroenterol Clin North Am 2006, 35: 229-247
24. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N. Kuipers EJ. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007; 56: 772-781
25. van der Wouden EJ, Thijs JC, van Zwet AA, Sluiter WJ, Kleibeuker JH. The influence of in vitro nitroimidazole resistance on the efficacy of nitroimidazole-containing anti-Helicobacter pylori regimens: a meta-analysis. Am J Gastroenterol 1999; 94: 1751-1759
26. Chi CH, Lin CY, Sheu BS, Yang HB, Huang AH, Wu JJ. Quadruple therapy containing amoxicillin and tetracycline is an effective regimen to rescue failed triple therapy by overcoming the antimicrobial resistance of Helicobacter pylori. Aliment Pharmacol Ther 2003; 18: 347-353
27. British Medical Association, Royal Pharmaceutical Society of Great Britain. British National Formulary. 42nd ed. Wallingford: Pharmaceutical Press, 2001: 41, 43, 169, 286
28. Bateson MC. Quadruple therapy for symptomatic spontaneous duodenal ulcer disease. Postgrad Med J 2001; 77: 447-450
29. Vaira D, Zullo A, Vakil N, Gatta L, Ricci C, Perna F, Hassan C, Bernabucci V, Tampieri A, Morini S. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial. Ann Intern Med 2007; 146: 556-563
30. Romano M, Marmo R, Cuomo A, De Simone T, Mucherino C, Iovene MR, Montella F, Tufano MA, Del Vecchio Blanco C, Nardone G. Pretreatment antimicrobial susceptibility testing is cost saving in the eradication of Helicobacter pylori. Clin Gastroenterol Hepatol 2003; 1: 273-278
31. Katelaris PH, Forbes GM, Talley NJ, Crotty B. A randomized comparison of quadruple and triple therapies for Helicobacter pylori eradication: The QUADRATE Study. Gastroenterology 2002; 123: 1763-1769
32. Uygun A, Kadayifci A, Safali M, Ilgan S, Bagci S. The efficacy of bismuth containing quadruple therapy as a first-line treatment option for Helicobacter pylori. J Dig Dis 2007; 8: 211-215
33. Calvet X, Ducons J, Guardiola J, Tito L, Andreu V, Bory F, Guirao R. One-week triple vs. quadruple therapy for Helicobacter pylori infection - a randomized trial. Aliment Pharmacol Ther 2002; 16: 1261-1267
34. Jang HJ, Choi MH, Kim YS, Sen YA, Baik KH, Baik IH. Eun CS. Kim JB, Kae SH, Kim DJ, Lee MS, Kim HY, Lee J. [Effectiveness of triple therapy and quadruple therapy for Helicobacter pylori eradication] Korean J Gastroenterol 2005; 46: 368-372